Skip to search formSkip to main contentSkip to account menu

ADR-529

Known as: ADR 529, ADR529 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

DexrazoxaneDexrazoxane hydrochloride

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2013
Review
2013
Carbon nanotubes as a novel drug delivery system for anticancer therapy: a review
Carbon nanotubes (CNTs) were discovered in 1991 and shown to have certain unique physicochemical properties, attracting… 
2001
2001
Oxidative mutagenesis of doxorubicin-Fe(III) complex.
Highly Cited
1996
Highly Cited
1996
Dose-response relationship of dexrazoxane for prevention of doxorubicin-induced cardiotoxicity in mice, rats, and dogs.
Dexrazoxane [(DZR), ADR 529, ICRF-187] ameliorates doxorubicin (DOX)-induced cardiotoxicity in animals, and is recommended as a… 
Review
1995
Review
1995
Cardiotoxicity and cardioprotection during chemotherapy.
Chemotherapy drugs have been reported to cause cardiac side effects including cardiomyopathy, ischemia, arrhythmias, and… 
Highly Cited
1994
Highly Cited
1994
Cell cycle progression and chromosome segregation in mammalian cells cultured in the presence of the topoisomerase II inhibitors ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane; ADR-529] and…
Certain bis(2,6-dioxopiperazine) derivatives, which include ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl]propane; ADR-529) and… 
Highly Cited
1993
Highly Cited
1993
Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and…
Highly Cited
1992
Highly Cited
1992
Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model.
In this study doxorubicin, epirubicin, and mitoxantrone were compared for their cardiotoxic potential in a chronic mouse model in… 
Highly Cited
1992
Highly Cited
1992
Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin.
BACKGROUND Although doxorubicin is an anticancer agent with a wide spectrum of activity, therapy with this anthracycline must… 
1992
1992
In vitro effects of three iron chelators on mitogen-activated lymphocytes: identification of differences in their mechanisms of action.
1992
1992
In vitro evidence for direct complexation of ADR-529/ICRF-187 [(+)-1,2-bis-(3,5-dioxo-piperazin-1-yl)propane] onto an existing ferric-anthracycline complex.
ADR-529 protects against anthracycline cardiotoxicity, possibly by preventing free radical induction. We hypothesize that this… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License